Page 1

SUDA PHARMACEUTICALS LTD ACN 090 987 250 ASX Release Appendix 4C : Fourth Quarter FY 2021 PERTH , AUSTRALIA - 26 July 2021 : SUDA Pharmaceuticals Ltd ( ASX : SUD ) , a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system , today released its Appendix 4C for the fourth quarter of FY 2021 . Cash receipts for the quarter were $ 68,000 with a bank balance of $ 6.717m at 30 June . The net outflow from operating activities for the quarter was $ 0.909m . In accordance with Listing Rule 4.7C , payments made to related parties and their associates included in item 6.1 of the Appendix 4C incorporates directors ' fees , remuneration and superannuation at commercial rates . iNKT cell therapy platform licence SUDA management has been actively looking to add new technologies to strengthen its pipeline in its two focus areas , oncology and conditions that affect the central nervous system . As announced on 18 June 2021 , SUDA acquired a global , exclusive licence to an invariant Natural Killer T ( iNKT ) cell therapy platform . Professor Anastasios Karadimitris developed the platform at Imperial College London . Preclinical studies from the laboratory of Professor Karadimitris demonstrated that the natural properties of iNKT cells allow them to target cancer cells . iNKT cells can be further modified to equip them with a Chimeric Antigen Receptor ( CAR ) , and CAR - INKT cells have two ways to recognise , attach to , and destroy cancer cells , making them dual targeting . In preclinical studies , CAR - INKT cells displayed superior activity relative to conventional cell therapies in eradicating cancer cells and extending tumour - free survival . The therapy is initially being developed for the treatment of blood cancers . Professor Karadimitris ' research group was the first to demonstrate that iNKT cells are protective against graft versus host disease ( GVHD ) . This provides a critical advantage that the iNKT cell platform may be used “ off - the - shelf ” , meaning that the cells can be isolated from a healthy donor , modified to enhance their activity against cancer and stored frozen , ready to be administered to cancer patients as needed . This would represent a significant advantage for the field . CEO and MD , Dr Michael Baker , commented : " We are delighted to have licenced what we believe is a promising platform that can be used to treat cancer . There is a lot of hard work to get to human clinical trials but we are motivated by the data from preclinical studies 26 July 2021 Page 1 of 3